PE20000017A1 - Combinaciones de estatina-eter carboxialquilico - Google Patents
Combinaciones de estatina-eter carboxialquilicoInfo
- Publication number
- PE20000017A1 PE20000017A1 PE1998001207A PE00120798A PE20000017A1 PE 20000017 A1 PE20000017 A1 PE 20000017A1 PE 1998001207 A PE1998001207 A PE 1998001207A PE 00120798 A PE00120798 A PE 00120798A PE 20000017 A1 PE20000017 A1 PE 20000017A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- composition
- carboxialkyl
- dialuvastatin
- fluvastatin
- Prior art date
Links
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 title abstract 4
- -1 DIALUVASTATIN Chemical compound 0.000 abstract 3
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 abstract 2
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract 2
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract 2
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 229960003765 fluvastatin Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 abstract 1
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 abstract 1
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 abstract 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 abstract 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 abstract 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 abstract 1
- 230000003143 atherosclerotic effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 229960005110 cerivastatin Drugs 0.000 abstract 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 abstract 1
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000004351 coronary vessel Anatomy 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 229960004844 lovastatin Drugs 0.000 abstract 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 abstract 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 abstract 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 abstract 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960002965 pravastatin Drugs 0.000 abstract 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 abstract 1
- 229960002855 simvastatin Drugs 0.000 abstract 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 150000003536 tetrazoles Chemical class 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6937597P | 1997-12-12 | 1997-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20000017A1 true PE20000017A1 (es) | 2000-01-20 |
Family
ID=22088573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1998001207A PE20000017A1 (es) | 1997-12-12 | 1998-12-11 | Combinaciones de estatina-eter carboxialquilico |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1045691B1 (https=) |
| JP (1) | JP2002508320A (https=) |
| KR (1) | KR20010033003A (https=) |
| AR (1) | AR017851A1 (https=) |
| AT (1) | ATE285762T1 (https=) |
| AU (1) | AU754089B2 (https=) |
| BR (1) | BR9813542A (https=) |
| CA (1) | CA2304612A1 (https=) |
| CO (1) | CO4970816A1 (https=) |
| CR (1) | CR5926A (https=) |
| CU (1) | CU20000140A7 (https=) |
| DE (1) | DE69828442T2 (https=) |
| DK (1) | DK1045691T3 (https=) |
| ES (1) | ES2230733T3 (https=) |
| GT (1) | GT199800196A (https=) |
| HN (1) | HN1998000185A (https=) |
| HU (1) | HUP0004547A3 (https=) |
| IL (1) | IL135349A0 (https=) |
| IS (1) | IS2150B (https=) |
| MY (1) | MY118381A (https=) |
| NO (1) | NO20002966D0 (https=) |
| NZ (1) | NZ503982A (https=) |
| PA (1) | PA8464601A1 (https=) |
| PE (1) | PE20000017A1 (https=) |
| PL (1) | PL341066A1 (https=) |
| PT (1) | PT1045691E (https=) |
| SV (1) | SV1998000146A (https=) |
| UY (1) | UY25299A1 (https=) |
| WO (1) | WO1999030704A1 (https=) |
| ZA (1) | ZA9811348B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861555B2 (en) | 2000-01-25 | 2005-03-01 | Warner-Lambert Company | Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith |
| EP1037623A1 (en) * | 1997-12-12 | 2000-09-27 | Warner-Lambert Company | Antihyperlipidemic statin-lp(a) inhibitor combinations |
| US20030105154A1 (en) | 2001-10-24 | 2003-06-05 | Bisgaier Charles Larry | Statin-carboxyalkylether combinations |
| CZ20011035A3 (cs) * | 1998-09-30 | 2001-10-17 | Warner-Lambert Company | Léčivo pro prevenci nebo oddálení revaskularizace pomocí katetru u pacientů postiľených chorobou koronární artérie |
| US6562864B1 (en) * | 1999-09-02 | 2003-05-13 | Drake Larson | Catechin multimers as therapeutic drug delivery agents |
| IN191580B (https=) * | 1999-12-17 | 2003-12-06 | Ranbaxy Lab Ltd | |
| CA2397960C (en) | 2000-01-25 | 2008-09-09 | Warner-Lambert Company | Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith |
| AU2001256278A1 (en) * | 2000-04-18 | 2001-10-30 | Bayer Aktiengesellschaft | Use of cse inhibitors for treating heart failure |
| OA12252A (en) * | 2000-04-26 | 2006-05-11 | Warner Lambert Co | Antihypertensive agents and use. |
| US6689807B1 (en) | 2000-06-08 | 2004-02-10 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | HMG CoA reductase inhibitors for promoting angiogenesis |
| US6777552B2 (en) | 2001-08-16 | 2004-08-17 | Teva Pharmaceutical Industries, Ltd. | Processes for preparing calcium salt forms of statins |
| HRPK20040255B3 (en) * | 2001-08-16 | 2006-02-28 | Teva Pharmaceutical Industries Ltd. | Processes for preparing calcium salt forms of statins |
| US20050026979A1 (en) * | 2003-07-31 | 2005-02-03 | Maha Ghazzi | Methods for treating inflammation and inflammation-associated diseases with a statin and ether |
| US10028926B2 (en) * | 2012-01-06 | 2018-07-24 | Gemphire Therapeutics Inc. | Methods of reducing risk of cardiovascular disease |
| AU2016348638A1 (en) | 2015-11-06 | 2018-06-07 | Gemphire Therapeutics Inc. | Gemcabene combinations for the treatment of cardiovascular disease |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
-
1998
- 1998-11-12 NZ NZ503982A patent/NZ503982A/en unknown
- 1998-11-20 DE DE69828442T patent/DE69828442T2/de not_active Expired - Lifetime
- 1998-11-20 PL PL98341066A patent/PL341066A1/xx unknown
- 1998-11-20 CA CA002304612A patent/CA2304612A1/en not_active Abandoned
- 1998-11-20 KR KR1020007006355A patent/KR20010033003A/ko not_active Ceased
- 1998-11-20 PT PT98960278T patent/PT1045691E/pt unknown
- 1998-11-20 IL IL13534998A patent/IL135349A0/xx unknown
- 1998-11-20 BR BR9813542-2A patent/BR9813542A/pt not_active Application Discontinuation
- 1998-11-20 JP JP2000538687A patent/JP2002508320A/ja active Pending
- 1998-11-20 HU HU0004547A patent/HUP0004547A3/hu unknown
- 1998-11-20 AT AT98960278T patent/ATE285762T1/de not_active IP Right Cessation
- 1998-11-20 AU AU15915/99A patent/AU754089B2/en not_active Ceased
- 1998-11-20 DK DK98960278T patent/DK1045691T3/da active
- 1998-11-20 ES ES98960278T patent/ES2230733T3/es not_active Expired - Lifetime
- 1998-11-20 WO PCT/US1998/024679 patent/WO1999030704A1/en not_active Ceased
- 1998-11-20 EP EP98960278A patent/EP1045691B1/en not_active Expired - Lifetime
- 1998-12-09 HN HN1998000185A patent/HN1998000185A/es unknown
- 1998-12-10 MY MYPI98005579A patent/MY118381A/en unknown
- 1998-12-10 ZA ZA9811348A patent/ZA9811348B/xx unknown
- 1998-12-10 CR CR5926A patent/CR5926A/es not_active Application Discontinuation
- 1998-12-11 CO CO98073828A patent/CO4970816A1/es unknown
- 1998-12-11 PE PE1998001207A patent/PE20000017A1/es not_active Application Discontinuation
- 1998-12-11 GT GT199800196A patent/GT199800196A/es unknown
- 1998-12-11 UY UY25299A patent/UY25299A1/es not_active Application Discontinuation
- 1998-12-11 PA PA19988464601A patent/PA8464601A1/es unknown
- 1998-12-11 AR ARP980106321A patent/AR017851A1/es unknown
- 1998-12-11 SV SV1998000146A patent/SV1998000146A/es not_active Application Discontinuation
-
2000
- 2000-04-14 IS IS5445A patent/IS2150B/is unknown
- 2000-06-09 CU CU20000140A patent/CU20000140A7/es unknown
- 2000-06-09 NO NO20002966A patent/NO20002966D0/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20000017A1 (es) | Combinaciones de estatina-eter carboxialquilico | |
| ATE380020T1 (de) | Stabile arzneiformulierungen enthaltend pravastatin or atorvastatin | |
| AR018777A1 (es) | Composicion farmaceutica que contiene una combinacion de una estatina y aspirina y metodo. | |
| MX2009003920A (es) | Estatina y acidos grasos omega 3 para reducir los niveles de apo b. | |
| PE20060465A1 (es) | Composiciones que contienen policosanol y un inhibidor de reductasa hmg-coa | |
| PE20020850A1 (es) | Utilizacion de compuestos de azetidinona sustituida para tratamiento de la sitosterolemia | |
| DK1200385T3 (da) | Krystaller af natriumsalt af pravastatin | |
| IS2113B (is) | Ný sölt HMG-CoA redúktasatálma | |
| PE20050128A1 (es) | Formulacion farmaceutica | |
| MX9702175A (es) | Combinacion de un inhibidor de absorcion de colesterol y un inhibidor de sintesis de colesterol. | |
| NO1997012I1 (no) | Atorvastatin | |
| RU2004139029A (ru) | Применение замещенных цианопирролидинов и содержащих их комбинированных препаратов для лечения гиперлипидемии и ассоциированных заболеваний | |
| ATE444299T1 (de) | Neue boronatester | |
| KR890005080A (ko) | HMG-CoA환원효소 억제제 | |
| PE20000348A1 (es) | Composicion farmaceutica que comprende un inhibidor de metaloproteasa de matriz (mmp) y una estatina | |
| JP2008513379A5 (https=) | ||
| CO5611117A2 (es) | Combinacion de compuestos organicos | |
| JP2003524582A5 (https=) | ||
| AR048668A1 (es) | Composiciones hipocolesterolemiantes y procedimiento para prepararlas | |
| ECSP982777A (es) | Combinaciones de estatina- - eter carboxialquilico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |